Revision of Guidelines Beneficial for Assessing Orthostatic Hypotension
|
By LabMedica International staff writers Posted on 07 Aug 2017 |
Researchers have found that measuring blood pressure to test for the presence of orthostatic hypotension (OH; a form of low blood pressure) should be performed within one minute of standing after a person has been lying down, instead of three minutes after.
“Our findings suggest that a blood pressure assessment within the first minute is a better way to assess health risks due to OH and that waiting three minutes might miss at-risk status,” said paper first-author Stephen Juraschek, MD, PhD, of Johns Hopkins University School of Medicine (Baltimore, MD, USA).
OH (sometimes called postural hypotension) is common among older adults, marked by dizziness, lightheadedness, and even fainting when they stand up. Although sometimes related to medication side effects, anemia, or dehydration, OH in many cases has unknown causes. It may increase risk of falls and strokes, both of which can be lethal.
Clinically, a person is diagnosed with OH when systolic blood pressure drops by at least 20 mmHg during transition from lying down to standing up, or when diastolic blood pressure drops by at least 10mmHg within three minutes after standing. While a healthy person’s blood pressure will return to their baseline readings almost immediately after such a test, blood pressure for people with OH will linger at lower values for a while.
The current three-minute threshold was implemented after a review of studies and a consensus statement from the American Academy of Neurology in the late 1990s. This statement was later reiterated in 2011. In practice, however, clinicians often do not wait the recommended 3 minutes to measure blood pressure due to time constraints.
To learn whether waiting or not waiting for the three-minute threshold made any significant difference in risk assessment, Dr. Juraschek and his team analyzed blood pressure data already gathered on over 15,000 people ages 45-64 during the Atherosclerosis Risk in Communities Study (ARIC; conducted during 1987-1989). They focused on data taken from 11,429 participants who had at least 4 measurements testing for OH over time, and looked for links between measurement times and adverse events – falls, fractures, fainting, and car crashes. They also looked for association between time of measurement and death. Of the participants, 54% were women and 26% were black, with an average age of 54 years. Nearly 10% of participants self-reported a history of dizziness upon standing.
The researchers found that measurements taken within 30 seconds of standing were associated with the highest rates per 1,000 person-years of fracture (18.9), fainting (17.0), and death (31.4). Measurements taken within 1 minute were associated with the highest rate of falls (13.2 per 1,000 person-years) and car crashes (2.5). Measurements taken within 30 seconds were associated with the greatest proportion, 13.5%, of self-reported dizziness.
The findings support the idea that OH assessments performed within one minute of standing are most strongly related to self-reported dizziness and individual adverse outcomes: “If someone comes into the clinic with dizziness, we try to assess his/her risk of falling or other consequences of dizziness in the future,” said Dr. Juraschek, “These results show that assessing OH within the first minute not only is OK, but also makes a lot of sense because it’s more predictive of future falls.”
Current treatments for chronic OH include physical therapy to improve balance, lifestyle changes including drinking more fluid and eating smaller meals, altering the environment (such as using grip bars), coaching patients how to safely stand up, and changing or stopping certain medications.
The study, by Juraschek S et al, was published July 24, 2017, in the journal JAMA Internal Medicine.
Related Links:
Johns Hopkins University School of Medicine
“Our findings suggest that a blood pressure assessment within the first minute is a better way to assess health risks due to OH and that waiting three minutes might miss at-risk status,” said paper first-author Stephen Juraschek, MD, PhD, of Johns Hopkins University School of Medicine (Baltimore, MD, USA).
OH (sometimes called postural hypotension) is common among older adults, marked by dizziness, lightheadedness, and even fainting when they stand up. Although sometimes related to medication side effects, anemia, or dehydration, OH in many cases has unknown causes. It may increase risk of falls and strokes, both of which can be lethal.
Clinically, a person is diagnosed with OH when systolic blood pressure drops by at least 20 mmHg during transition from lying down to standing up, or when diastolic blood pressure drops by at least 10mmHg within three minutes after standing. While a healthy person’s blood pressure will return to their baseline readings almost immediately after such a test, blood pressure for people with OH will linger at lower values for a while.
The current three-minute threshold was implemented after a review of studies and a consensus statement from the American Academy of Neurology in the late 1990s. This statement was later reiterated in 2011. In practice, however, clinicians often do not wait the recommended 3 minutes to measure blood pressure due to time constraints.
To learn whether waiting or not waiting for the three-minute threshold made any significant difference in risk assessment, Dr. Juraschek and his team analyzed blood pressure data already gathered on over 15,000 people ages 45-64 during the Atherosclerosis Risk in Communities Study (ARIC; conducted during 1987-1989). They focused on data taken from 11,429 participants who had at least 4 measurements testing for OH over time, and looked for links between measurement times and adverse events – falls, fractures, fainting, and car crashes. They also looked for association between time of measurement and death. Of the participants, 54% were women and 26% were black, with an average age of 54 years. Nearly 10% of participants self-reported a history of dizziness upon standing.
The researchers found that measurements taken within 30 seconds of standing were associated with the highest rates per 1,000 person-years of fracture (18.9), fainting (17.0), and death (31.4). Measurements taken within 1 minute were associated with the highest rate of falls (13.2 per 1,000 person-years) and car crashes (2.5). Measurements taken within 30 seconds were associated with the greatest proportion, 13.5%, of self-reported dizziness.
The findings support the idea that OH assessments performed within one minute of standing are most strongly related to self-reported dizziness and individual adverse outcomes: “If someone comes into the clinic with dizziness, we try to assess his/her risk of falling or other consequences of dizziness in the future,” said Dr. Juraschek, “These results show that assessing OH within the first minute not only is OK, but also makes a lot of sense because it’s more predictive of future falls.”
Current treatments for chronic OH include physical therapy to improve balance, lifestyle changes including drinking more fluid and eating smaller meals, altering the environment (such as using grip bars), coaching patients how to safely stand up, and changing or stopping certain medications.
The study, by Juraschek S et al, was published July 24, 2017, in the journal JAMA Internal Medicine.
Related Links:
Johns Hopkins University School of Medicine
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







